• Editas Medicine's ROIC is significantly lower than its WACC, indicating poor capital efficiency.
• Compared to peers, CRISPR Therapeutics shows the least negative ROIC to WACC ratio, suggesting better capital management.
• All companies in the gene editing space, including Beam Therapeutics and Pacific Biosciences, face challenges in generating returns above their cost of capital.

Editas Medicine, Inc. (NASDAQ:EDIT) is a biotechnology company focused on developing gene editing technologies. The company aims to translate its proprietary CRISPR technology into transformative medicines. Editas competes with other companies in the gene editing space, such as Intellia Therapeutics, CRISPR Therapeutics, Beam Therapeutics, and Pacific Biosciences of California.

Editas Medicine's ROIC is -154.03%, which is significantly lower than its WACC of 13.54%. This indicates that the company is not generating sufficient returns on its invested capital. The ROIC to WACC ratio of -11.38 further highlights the disparity between the returns and the cost of capital, raising concerns for investors.

In comparison, Intellia Therapeutics has a ROIC of -42.76% and a WACC of 11.66%, resulting in a ROIC to WACC ratio of -3.67. While still negative, Intellia's ratio is less severe than Editas, suggesting a slightly better capital efficiency. CRISPR Therapeutics, with a ROIC of -23.46% and a WACC of 11.43%, has the best ROIC to WACC ratio among the peers at -2.05.

Beam Therapeutics and Pacific Biosciences also show negative ROICs of -40.86% and -86.29%, respectively. Their ROIC to WACC ratios are -3.07 and -10.68, indicating challenges in generating returns above their cost of capital. Despite these challenges, CRISPR Therapeutics stands out with the least negative ratio, suggesting relatively better capital management.